BR112020005132A2 - prevenção e/ou tratamento de doença neurodegenerativa - Google Patents
prevenção e/ou tratamento de doença neurodegenerativa Download PDFInfo
- Publication number
- BR112020005132A2 BR112020005132A2 BR112020005132-2A BR112020005132A BR112020005132A2 BR 112020005132 A2 BR112020005132 A2 BR 112020005132A2 BR 112020005132 A BR112020005132 A BR 112020005132A BR 112020005132 A2 BR112020005132 A2 BR 112020005132A2
- Authority
- BR
- Brazil
- Prior art keywords
- composition
- fact
- zeaxanthin
- omega
- fatty acid
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/07—Retinol compounds, e.g. vitamin A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/60—Fish, e.g. seahorses; Fish eggs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Marine Sciences & Fisheries (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1720119.5A GB201720119D0 (en) | 2017-12-04 | 2017-12-04 | Prevention and/or treatment of neurodegenerative disease |
| GB1720119.5 | 2017-12-04 | ||
| PCT/GB2018/051255 WO2019110951A1 (en) | 2017-12-04 | 2018-05-10 | Prevention and/or treatment of neurodegenerative disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112020005132A2 true BR112020005132A2 (pt) | 2020-09-15 |
Family
ID=60950313
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112020005132-2A BR112020005132A2 (pt) | 2017-12-04 | 2018-05-10 | prevenção e/ou tratamento de doença neurodegenerativa |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US10835509B2 (https=) |
| EP (2) | EP3644979B1 (https=) |
| JP (2) | JP7824729B2 (https=) |
| KR (1) | KR20200095452A (https=) |
| AU (1) | AU2018379644B2 (https=) |
| BR (1) | BR112020005132A2 (https=) |
| CA (1) | CA3071786C (https=) |
| ES (1) | ES3047101T3 (https=) |
| GB (2) | GB201720119D0 (https=) |
| IE (1) | IE87241B1 (https=) |
| MX (1) | MX2020002458A (https=) |
| RU (1) | RU2020111305A (https=) |
| SG (1) | SG11202000786RA (https=) |
| WO (1) | WO2019110951A1 (https=) |
| ZA (1) | ZA202000558B (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR3106957B1 (fr) * | 2020-02-07 | 2024-05-03 | Abdelhadi Zahouani | Composition alimentaire pour stimuler la fonction cognitive et prevenir et limiter le declin cognitif et la demence chez des sujets adultes ou chez des sujets ages denutris |
| US12076299B2 (en) * | 2020-02-20 | 2024-09-03 | Arjuna Natural Pvt Ltd | Composition and method to enhance cognitive support and brain health |
| KR20240008846A (ko) * | 2021-05-17 | 2024-01-19 | 오노 야꾸힝 고교 가부시키가이샤 | 인지 기능을 개선하기 위한 조성물 |
| JPWO2024143060A1 (https=) * | 2022-12-26 | 2024-07-04 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050163873A1 (en) | 2004-01-14 | 2005-07-28 | Robert Ritch | Methods and formulations for treating glaucoma |
| US8324276B2 (en) * | 2005-01-24 | 2012-12-04 | Pronova Biopharma Norge As | Fatty acid composition for treatment of alzheimer's disease and cognitive dysfunction |
| WO2006116755A2 (en) * | 2005-04-28 | 2006-11-02 | Trustees Of Tufts College | Synergitic effects of docosahexaenoic acid (dha) and carotenoid absorption of cognitive function |
| PL2219478T3 (pl) * | 2007-12-17 | 2017-10-31 | Newtricious Bv | Sposób wytwarzania funkcjonalnego produktu spożywczego na bazie żółtka jaja i produkty otrzymywane tym sposobem |
| GB201014340D0 (en) | 2010-08-27 | 2010-10-13 | Piraee Mahmood | Nutritional supplement formulation comprising saffron and resveratrol |
| HUE038813T2 (hu) * | 2011-07-07 | 2018-11-28 | Howard Foundation Holdings Ltd | Eljárás rontó káprázás javítására |
| DE212013000066U1 (de) * | 2012-07-19 | 2014-09-25 | U.S. Nutraceuticals Llc Dba Valensa International | Krillöl und reagierte Astaxanthinzusammensetzung |
| GB201300055D0 (en) | 2013-01-03 | 2013-02-20 | Howard Foundation Holdings Ltd | Identifying subjects in need of treatment |
| US20140187648A1 (en) * | 2013-01-03 | 2014-07-03 | Howard Foundation Holdings Ltd. | Identifying Subjects in Need of Treatment |
| MX2015013624A (es) * | 2013-03-28 | 2016-06-10 | Omniactive Health Technologies Ltd | Efecto neuroprotector de carotenoides en el cerebro. |
| JP6178761B2 (ja) | 2013-07-10 | 2017-08-09 | ライオン株式会社 | 内服剤 |
| US20190314442A1 (en) * | 2016-02-22 | 2019-10-17 | Newtricious B.V. | Composition for the prevention or treatment of neurodegenerative diseases |
-
2017
- 2017-12-04 GB GBGB1720119.5A patent/GB201720119D0/en not_active Ceased
-
2018
- 2018-05-10 MX MX2020002458A patent/MX2020002458A/es unknown
- 2018-05-10 CA CA3071786A patent/CA3071786C/en active Active
- 2018-05-10 ES ES18725605T patent/ES3047101T3/es active Active
- 2018-05-10 AU AU2018379644A patent/AU2018379644B2/en active Active
- 2018-05-10 SG SG11202000786RA patent/SG11202000786RA/en unknown
- 2018-05-10 RU RU2020111305A patent/RU2020111305A/ru unknown
- 2018-05-10 BR BR112020005132-2A patent/BR112020005132A2/pt not_active Application Discontinuation
- 2018-05-10 KR KR1020207007980A patent/KR20200095452A/ko active Pending
- 2018-05-10 GB GB1807590.3A patent/GB2568986B/en active Active
- 2018-05-10 EP EP18725605.2A patent/EP3644979B1/en active Active
- 2018-05-10 JP JP2020521460A patent/JP7824729B2/ja active Active
- 2018-05-10 WO PCT/GB2018/051255 patent/WO2019110951A1/en not_active Ceased
- 2018-05-10 EP EP25186112.6A patent/EP4599891A3/en active Pending
- 2018-05-15 IE IE20180146A patent/IE87241B1/en unknown
- 2018-05-15 US US15/980,083 patent/US10835509B2/en active Active
-
2020
- 2020-01-28 ZA ZA2020/00558A patent/ZA202000558B/en unknown
-
2025
- 2025-10-31 JP JP2025184568A patent/JP2026016698A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| GB201720119D0 (en) | 2018-01-17 |
| GB2568986A (en) | 2019-06-05 |
| IE20180146A1 (en) | 2019-06-12 |
| MX2020002458A (es) | 2020-07-20 |
| CA3071786A1 (en) | 2019-06-13 |
| EP3644979A1 (en) | 2020-05-06 |
| EP4599891A3 (en) | 2025-10-22 |
| SG11202000786RA (en) | 2020-06-29 |
| AU2018379644A1 (en) | 2020-03-19 |
| NZ761512A (en) | 2024-01-26 |
| WO2019110951A1 (en) | 2019-06-13 |
| GB2568986B (en) | 2019-12-18 |
| AU2018379644B2 (en) | 2024-02-08 |
| CA3071786C (en) | 2023-11-14 |
| ES3047101T3 (en) | 2025-12-03 |
| ZA202000558B (en) | 2021-10-27 |
| RU2020111305A (ru) | 2022-01-10 |
| JP2026016698A (ja) | 2026-02-03 |
| EP4599891A2 (en) | 2025-08-13 |
| EP3644979B1 (en) | 2025-08-06 |
| US20190167624A1 (en) | 2019-06-06 |
| GB201807590D0 (en) | 2018-06-27 |
| JP2021505527A (ja) | 2021-02-18 |
| JP7824729B2 (ja) | 2026-03-05 |
| US10835509B2 (en) | 2020-11-17 |
| KR20200095452A (ko) | 2020-08-10 |
| IE87241B1 (en) | 2021-07-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Martí et al. | Omega-3 fatty acids and cognitive decline: a systematic review | |
| Otaegui-Arrazola et al. | Diet, cognition, and Alzheimer’s disease: food for thought | |
| Mischoulon et al. | Docosahexanoic acid and ω-3 fatty acids in depression | |
| Park et al. | Parenteral fish oil–containing lipid emulsions may reverse parenteral nutrition–associated cholestasis in neonates: a systematic review and meta-analysis | |
| JP2026016698A (ja) | 神経変性疾患の予防及び／又は治療 | |
| Wolf-Schnurrbusch et al. | Oral lutein supplementation enhances macular pigment density and contrast sensitivity but not in combination with polyunsaturated fatty acids | |
| US20130108706A1 (en) | Dietary formulations | |
| BR112012022336A2 (pt) | composições e seus usos para tratar e/ou prevenir doença cardiovascular | |
| Cardinault et al. | Short-term supplementation with lutein affects biomarkers of lutein status similarly in young and elderly subjects | |
| Demirel et al. | The metabolic effects of two different lipid emulsions used in parenterally fed premature infants—a randomized comparative study | |
| Kawabata et al. | Effects of dietary supplementation with a combination of fish oil, bilberry extract, and lutein on subjective symptoms of asthenopia in humans | |
| Bowen et al. | Carotenoids in human nutrition | |
| CN107427485A (zh) | 用于治疗焦虑症的中链脂肪酸及其甘油三酯 | |
| Włodarek | The possibility of use of the ketogenic diet and medium chain triglycerides supplementation in the support therapy of Alzheimer disease | |
| US20200197349A1 (en) | Cognitive function | |
| Partinen et al. | Nutrition, sleep and sleep disorders–relations of some food constituents and sleep | |
| HK40130790A (en) | Prevention and/or treatment of neurodegenerative disease | |
| Lange et al. | The role of omega-3 polyunsaturated fatty acids in mental disorders | |
| US20190307715A1 (en) | Prevention and/or treatment of neurodegenerative disease | |
| US20140121276A1 (en) | Method for alleviating fear memory | |
| Abreu-González et al. | Nutritional supplements with omega 3 in retinal disease: Relationship between volume and concentration in commercial products | |
| Martí et al. | Omega-3 y deterioro cognivo: una revisión sistemática | |
| Galvin | Medical foods and dietary approaches in cognitive decline, mild cognitive impairment, and dementia | |
| Sousa | Anti-inflammatory diet and rheumatoid arthritis: overview on the current evidence | |
| JP2008044894A (ja) | メタボリックシンドローム改善剤 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B11A | Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing | ||
| B11Y | Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette] | ||
| B350 | Update of information on the portal [chapter 15.35 patent gazette] |